Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt No Debt
CRME's Cash to Debt is ranked higher than
88% of the 750 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.39 vs. CRME: No Debt )
CRME' s 10-Year Cash to Debt Range
Min: 1.26   Max: No Debt
Current: No Debt

Equity to Asset 0.48
CRME's Equity to Asset is ranked higher than
54% of the 712 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.60 vs. CRME: 0.48 )
CRME' s 10-Year Equity to Asset Range
Min: 0.18   Max: 0.98
Current: 0.48

0.18
0.98
F-Score: 4
Z-Score: -5.51
M-Score: 6.66
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -370.14
CRME's Operating margin (%) is ranked lower than
57% of the 713 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.34 vs. CRME: -370.14 )
CRME' s 10-Year Operating margin (%) Range
Min: -12543.75   Max: 55.51
Current: -370.14

-12543.75
55.51
Net-margin (%) 105.81
CRME's Net-margin (%) is ranked higher than
99% of the 713 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.50 vs. CRME: 105.81 )
CRME' s 10-Year Net-margin (%) Range
Min: -12075   Max: 105.81
Current: 105.81

-12075
105.81
ROE (%) 21.08
CRME's ROE (%) is ranked higher than
96% of the 716 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.00 vs. CRME: 21.08 )
CRME' s 10-Year ROE (%) Range
Min: -233.04   Max: 69.72
Current: 21.08

-233.04
69.72
ROA (%) 10.08
CRME's ROA (%) is ranked higher than
92% of the 745 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.95 vs. CRME: 10.08 )
CRME' s 10-Year ROA (%) Range
Min: -114.17   Max: 43.12
Current: 10.08

-114.17
43.12
ROC (Joel Greenblatt) (%) -2701.78
CRME's ROC (Joel Greenblatt) (%) is ranked lower than
57% of the 735 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 14.63 vs. CRME: -2701.78 )
CRME' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -9579.34   Max: 1772.4
Current: -2701.78

-9579.34
1772.4
Revenue Growth (%) -59.80
CRME's Revenue Growth (%) is ranked lower than
59% of the 549 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.10 vs. CRME: -59.80 )
CRME' s 10-Year Revenue Growth (%) Range
Min: -75   Max: 227.1
Current: -59.8

-75
227.1
EBITDA Growth (%) -48.50
CRME's EBITDA Growth (%) is ranked lower than
56% of the 504 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.00 vs. CRME: -48.50 )
CRME' s 10-Year EBITDA Growth (%) Range
Min: -48.5   Max: 33.3
Current: -48.5

-48.5
33.3
EPS Growth (%) -49.60
CRME's EPS Growth (%) is ranked lower than
55% of the 506 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.70 vs. CRME: -49.60 )
CRME' s 10-Year EPS Growth (%) Range
Min: -49.6   Max: 32.6
Current: -49.6

-49.6
32.6
» CRME's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

CRME Guru Trades in Q1 2013

Jim Simons 987,166 sh (+11.66%)
» More
Q2 2013

CRME Guru Trades in Q2 2013

Jim Simons 199,813 sh (-79.76%)
» More
Q3 2013

CRME Guru Trades in Q3 2013

Jim Simons 210,113 sh (+5.15%)
» More
Q4 2013

CRME Guru Trades in Q4 2013

Jim Simons 218,913 sh (+4.19%)
» More
» Details

Insider Trades

Latest Guru Trades with CRME

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Julian Robertson 2012-12-31 Sold Out 0.11%$0.25 - $0.5 $ 7.472310%0
George Soros 2011-12-31 Sold Out 0.0008%$1.87 - $3.57 $ 7.47179%0
Julian Robertson 2011-09-30 Reduce -22.89%0.69%$3.32 - $5.59 $ 7.4787%1952588
George Soros 2011-06-30 New Buy$3.85 - $5.77 $ 7.4758%13200
Julian Robertson 2011-03-31 Add 6.15%0.16%$4.26 - $6.99 $ 7.4727%2532340
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 17.20
CRME's P/E(ttm) is ranked higher than
84% of the 527 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 25.60 vs. CRME: 17.20 )
CRME' s 10-Year P/E(ttm) Range
Min: 1.39   Max: 12525
Current: 17.2

1.39
12525
P/B 5.00
CRME's P/B is ranked lower than
52% of the 700 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.84 vs. CRME: 5.00 )
CRME' s 10-Year P/B Range
Min: 1.01   Max: 34.63
Current: 5

1.01
34.63
P/S 21.40
CRME's P/S is ranked lower than
82% of the 717 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.95 vs. CRME: 21.40 )
CRME' s 10-Year P/S Range
Min: 3.34   Max: 274.32
Current: 21.4

3.34
274.32
EV-to-EBIT 0.30
CRME's EV-to-EBIT is ranked higher than
98% of the 593 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 19.45 vs. CRME: 0.30 )
CRME' s 10-Year EV-to-EBIT Range
Min: 4.6   Max: 171.9
Current: 0.3

4.6
171.9

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 26.70
CRME's Price/Tangible Book is ranked lower than
87% of the 639 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.10 vs. CRME: 26.70 )
CRME' s 10-Year Price/Tangible Book Range
Min: 2.9   Max: 71.09
Current: 26.7

2.9
71.09
Price/Median PS Value 0.70
CRME's Price/Median PS Value is ranked higher than
90% of the 675 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.10 vs. CRME: 0.70 )
CRME' s 10-Year Price/Median PS Value Range
Min: 0.18   Max: 50.61
Current: 0.7

0.18
50.61
Price/Graham Number 5.20
CRME's Price/Graham Number is ranked lower than
71% of the 470 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.20 vs. CRME: 5.20 )
CRME' s 10-Year Price/Graham Number Range
Min: 1.98   Max: 13.01
Current: 5.2

1.98
13.01
Earnings Yield (Greenblatt) 384.10
CRME's Earnings Yield (Greenblatt) is ranked higher than
99% of the 595 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.80 vs. CRME: 384.10 )
CRME' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.6   Max: 420.7
Current: 384.1

0.6
420.7
Forward Rate of Return (Yacktman) -9.52
CRME's Forward Rate of Return (Yacktman) is ranked higher than
55% of the 531 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.45 vs. CRME: -9.52 )
CRME' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -19.2   Max: -5.9
Current: -9.52

-19.2
-5.9

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:GSK, JNJ, PFE, RHHBY, NVS » details
Traded in other countries:COM.Canada, CKO.Germany
Cardiome Pharma Corporation was incorporated in December 12, 1986 under the name Nortran Resources Ltd. In June 2001, it changed its name to Cardiome Pharma Corp. It is a biopharmaceutical company which discovers, develops and commercializes new therapies that improve the health of patients around the world. It has one product, BRINAVESS, approved for marketing in Europe and other territories for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults. Its clinical programs are focused on the treatment of atrial fibrillation, an arrhythmia (or abnormal rhythm) of the upper chambers of the heart. Vernakalant is a new chemical entity designed by it to treat atrial fibrillation, with the potential to overcome the limitations of current drugs used to treat atrial fibrillation. The drug was being developed for two potential applications: vernakalant (IV) is being evaluated as an intravenous pharmacological converting agent designed to terminate an atrial fibrillation episode and return the heart to normal rhythm; and vernakalant (oral) is being evaluated as an oral maintenance therapy for the long-term prevention of atrial fibrillation recurrence. The research, development, manufacture, distribution, sale, and marketing of pharmaceutical products are subject to extensive regulation. In the United States, Europe and Canada, these activities are subject to rigorous regulation by the FDA, the EMA, and TPD, respectively. In addition, the research, manufacturing, distribution, sale, and promotion of pharmaceutical products are also potentially subject to regulation by various regional, national, and local authorities where the products are being developed and marketed.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide